Enabling Safer, Faster, More Efficient Discovery

As drug discovery pipelines face tighter budgets and greater pressure to deliver confident decisions earlier, structure-based drug design is becoming a central driver of modern R&D strategy. Biopharma teams are increasingly combining high-resolution structural biology with AI-enabled modelling and computational design to tackle complex targets, prioritise compounds faster, and reduce risk across discovery programs. 

While predictive technologies continue to advance, their true value lies in how effectively they integrate with experimental structural data. From cryo-EM breakthroughs and expanding structural resolution to the growing role of validated AI in modelling and construct design, the ability to connect computational prediction, structural insight and wet-lab validation is now critical for unlocking challenging targets and accelerating discovery. 

The 3rd Structure-Based Drug Design Summit Boston returns as the only industry-dedicated forum focused exclusively on the practical application of structural biology and AI across early drug discovery workflows. Bringing together structural biologists, medicinal chemists, computational scientists and discovery leaders, the meeting showcases how leading organizations are applying cryo-EM, structural data and predictive modelling to guide target selection, optimize compounds and strengthen discovery decisions. 

Through expert-led case studies, interactive discussions and collaborative networking, you’ll gain practical insight into solving complex targets across modalities from membrane proteins and GPCRs to induced-proximity therapeutics, biologics and next-generation modalities.